Trial Profile
VRC 606: A Phase 1, Dose-Escalation Study of the Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB080-00-AB (VRC01LS) and VRC-HIVMAB060-00-AB (VRC01), Administered Intravenously or Subcutaneously to Healthy Adults
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Apr 2021
Price :
$35
*
At a glance
- Drugs VRC 01LS (Primary) ; VRC 01LS (Primary) ; VRC 01; VRC 01
- Indications HIV infections; HIV-1 infections
- Focus Adverse reactions
- 10 Mar 2021 Results of pooled analysis from two studies (IMPAACT P1112 and VRC606) assessing Population Pharmacokinetics of Vrc01ls in Term Infants and Adults presented at the 28th Conference on Retroviruses and Opportunistic Infections
- 26 Jul 2018 Status changed from active, no longer recruiting to completed.
- 07 Sep 2017 Status changed from recruiting to active, no longer recruiting.